Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
Akira Ooki(Japanese Foundation For Cancer Research), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Yoshinori Kagawa(Osaka International Cancer Institute), Hironaga Satake(Kobe City Medical Center General Hospital), Hiroki Hara(Saitama Cancer Center), Masahito Kotaka(Shimizu (Japan)), Junichi Sakamoto(Tokai Central Hospital), Akihito Tsuji(Kagawa University Hospital), Yasuhiro Miyake(Nishinomiya Municipal Central Hospital), Taichi Yabuno(Yokohama Municipal Citizen's Hospital), Masahiko Ando(Nagoya University Hospital), Shigeyoshi Iwamoto(Aichi Medical University), Yojiro Hashiguchi(Teikyo University), Satoshi Morita(Kyoto University), Masashi Ishikawa(International Research Center for Japanese Studies), Takeshi Suto(Yamagata Prefectural Central Hospital), Hiroaki Tanioka(Okayama Rosai Hospital), Masato Nakamura(Chiba University), Masato Kataoka(National Hospital Organization), Tatsushi Shingai(Kinki Central Hospital)
Cited by 10
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k